Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

The Healthcare Businesswomen's Association (HBA) successfully convened the second edition of its annual India Leadership Summit (ILS) at The Lalit Hotel, Mumbai. Under the powerful theme "Winning a ...

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with ...

Companies don’t generally cut prices out of generosity.

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease ...

Pharma companies are spending billions on a treatment based off old drugs, with little evidence it will extend lives.

That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Metsera, the US biotech with a pipeline of next-generation metabolic hormone weight loss drugs, has agreed a sale to Pfizer ...